Unicharm (8113) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
12 Feb, 2026Executive summary
FY2025 consolidated net sales were 945.3 billion yen, down 4.4% year-over-year, with core operating income of 108.9 billion yen, down 21.4%, and profit attributable to owners of parent at 65.2 billion yen, down 20.3%, mainly due to intensified competition in Asia and China, while Japan and the Middle East showed stable or strong performance.
Proactive investments and structural reforms were accelerated, especially in Asia, to lay the foundation for the 13th Mid-term Management Plan starting FY2026.
A one-time valuation loss of 6,920 million yen was recognized due to a GST system revision in India.
Financial highlights
Net sales: 945.3 billion yen (YoY -4.4%); core operating income: 108.9 billion yen (YoY -21.4%); profit attributable to owners: 65.2 billion yen (YoY -20.3%).
EBITDA: 166.1 billion yen (YoY -8.7%).
Base EPS: 37.30 yen (YoY -19.6%), reflecting the 3-for-1 stock split.
Annual dividend: 18 yen per share, marking 24 consecutive years of increases.
Total assets at year-end: 1,223,176 million yen; total equity: 891,259 million yen; equity ratio: 65.0%.
Outlook and guidance
FY2026 forecasts: net sales 1,010 billion yen (+6.8% YoY), core operating income 136.0 billion yen (+24.9% YoY), profit attributable to owners 86.5 billion yen (+32.6% YoY), and basic EPS 49.71 yen.
Recovery in Asia expected to drive growth; raw material costs projected to decrease by 13.0 billion yen.
Capital expenditure planned at 40.0 billion yen; depreciation at 47.0 billion yen.
Dividend per share planned to increase to 22 yen for the 25th consecutive year, with a target payout ratio of up to 65% and DOE of 4.5% or more.
Latest events from Unicharm
- Sales and core profit declined, but profit attributable to owners rose 2.0% YoY.8113
Q3 20257 Nov 2025 - Sales and profits fell, but resilient regions and cost controls support a recovery outlook.8113
Q2 20255 Aug 2025 - Record sales and profit growth continue, with strong overseas and segment performance.8113
Q2 202413 Jun 2025 - Record sales and profit growth, with strong personal and pet care and rising dividends.8113
Q3 202413 Jun 2025 - Net profit jumped in Q1 FY2025 despite lower sales, aided by insurance proceeds.8113
Q1 20256 Jun 2025 - Record sales and profit growth, with a stock split and strong FY2025 outlook.8113
Q4 20245 Jun 2025